File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.canlet.2013.09.007
- Scopus: eid_2-s2.0-84890860747
- PMID: 24041865
- WOS: WOS:000331163500004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models
Title | Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models |
---|---|
Authors | |
Keywords | BEZ235 MAPK activation Nasopharyngeal carcinoma |
Issue Date | 2014 |
Citation | Cancer Letters, 2014, v. 343 n. 1, p. 24-32 How to Cite? |
Abstract | The dual PI3K-mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signaling in most NPC cell lines. No synergistic effect was observed when BEZ235 was combined with chemotherapy. BEZ235 increased MAPK activation in vitro but not in vivo. A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status. © 2013 Elsevier Ireland Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/194454 |
ISSN | 2023 Impact Factor: 9.1 2023 SCImago Journal Rankings: 2.595 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ma, BBY | - |
dc.contributor.author | Lui, VWY | - |
dc.contributor.author | Hui, CWC | - |
dc.contributor.author | Lau, CPY | - |
dc.contributor.author | Wong, CH | - |
dc.contributor.author | Hui, EP | - |
dc.contributor.author | Ng, MHL | - |
dc.contributor.author | Cheng, SH | - |
dc.contributor.author | Tsao, SW | - |
dc.contributor.author | Tsang, C-M | - |
dc.contributor.author | Cheung, CSF | - |
dc.contributor.author | Ho, K | - |
dc.contributor.author | Chan, ATC | - |
dc.date.accessioned | 2014-01-30T03:32:36Z | - |
dc.date.available | 2014-01-30T03:32:36Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Cancer Letters, 2014, v. 343 n. 1, p. 24-32 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | http://hdl.handle.net/10722/194454 | - |
dc.description.abstract | The dual PI3K-mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signaling in most NPC cell lines. No synergistic effect was observed when BEZ235 was combined with chemotherapy. BEZ235 increased MAPK activation in vitro but not in vivo. A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status. © 2013 Elsevier Ireland Ltd. | - |
dc.language | eng | - |
dc.relation.ispartof | Cancer Letters | - |
dc.subject | BEZ235 | - |
dc.subject | MAPK activation | - |
dc.subject | Nasopharyngeal carcinoma | - |
dc.title | Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.canlet.2013.09.007 | - |
dc.identifier.pmid | 24041865 | - |
dc.identifier.scopus | eid_2-s2.0-84890860747 | - |
dc.identifier.hkuros | 246480 | - |
dc.identifier.volume | 343 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 24 | - |
dc.identifier.epage | 32 | - |
dc.identifier.isi | WOS:000331163500004 | - |
dc.identifier.issnl | 0304-3835 | - |